POLE3
ENSG00000148229
Target class
Unclassified protein
Chromosome
9
Approved drugs
4
Clinical candidates (approved and in development)
6
- Approved drugs
- 4
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- No
- Target name
- POLE3
- Gene name
- DNA polymerase epsilon 3, accessory subunit
- Gene symbol
- POLE3
- Protein name
- DNA polymerase epsilon subunit 3 (Arsenic-transactivated protein) (AsTP) (Chromatin accessibility complex 17 kDa protein) (CHRAC-17) (HuCHRAC17) (DNA polymerase II subunit 3) (DNA polymerase epsilon subunit p17)
- CHRAC17
- Ybl1
- p17
- CHARAC17
- CHRAC2
- Gene biotype
- Protein coding
- Gene family
- DNA polymerases|ATAC complex|Chromatin accessibility complex
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 81.35
- Tissue specificity (Gini)
- 0.237
- Tissue specificity (tau)
- 0.55
- KEGG gene identifiers
- hsa:54107
- Protein interaction confidence
- 0.839164
- Protein interaction partners
- 73
- R-HSA-110314
- R-HSA-5651801
- R-HSA-5656169
- R-HSA-5685942
- R-HSA-5696397
- R-HSA-5696400
- R-HSA-6782135
- R-HSA-6782210
- R-HSA-68952
- R-HSA-68962
- End position
- 113410723
- Start position
- 113407232
- Chromosome
- 9
- Strand
- Reverse
- Nucleus .
- Cytosol
- Nucleoli
- Nucleoplasm
- Tissue specificity (tau)
- 0.550313
- Expression inequality (Gini)
- 0.237086
Expression in transcripts per million
- Brain - Cerebellar Hemisphere
- 81.35
- Cells - EBV-transformed lymphocytes
- 75.44
- Cells - Cultured fibroblasts
- 64.92
- Testis
- 64.51
- Brain - Cerebellum
- 61.82
Expression in transcripts per million
- Brain - Cerebellar Hemisphere81.35
- Cells - EBV-transformed lymphocytes75.44
- Cells - Cultured fibroblasts64.92
- Testis64.51
- Brain - Cerebellum61.82
- Skin - Sun Exposed (Lower leg)56.48
- Skin - Not Sun Exposed (Suprapubic)56.01
- Artery - Tibial53.84
- Spleen52.11
- Esophagus - Mucosa50.54
- Fallopian Tube46.35
- Uterus45.85
- Muscle - Skeletal45.22
- Cervix - Endocervix45.18
- Bladder44.66
- Colon - Sigmoid44.53
- Artery - Coronary44.04
- Nerve - Tibial43.85
- Cervix - Ectocervix43.62
- Vagina43.57
- Adrenal Gland42.01
- Artery - Aorta41.89
- Lung41.45
- Esophagus - Muscularis41.42
- Adipose - Subcutaneous41.15
And 29 more, listed on the interactive page.
- GO:0000122
- GO:0006260
- GO:0006261
- GO:0006275
- GO:0006334
- GO:0006338
- GO:0005634
- GO:0005654
- GO:0008622
- GO:0140672
- GO:0003887
- GO:0005515
Related records
Trials (4,736)
- (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma
- (PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer
- 1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy
- 2 Arm Study of Clofarabine IV in MDS Patients
- 2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)
- 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
- 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
- ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
- 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
- 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
- 2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen
- 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
- 3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer
- 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
- 3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer
- 3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer
- 3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer
- 3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
- 3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome
Drugs (7)
- Aspacytarabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Clofarabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Cytarabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Fludarabine phosphate DNA polymerase (alpha/delta/epsilon) inhibitor
- Gemcitabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Gemcitabine hydrochloride DNA polymerase (alpha/delta/epsilon) inhibitor
- Troxacitabine DNA polymerase (alpha/delta/epsilon) inhibitor